Profusa Inc. (NASDAQ: PFSA) announced its listing transfer to the Nasdaq Capital Market, effective May 15, 2026. The digital health company develops technology for continuous monitoring of biochemistry.

The transfer represents the first step in a series of interim milestones established by the Nasdaq Hearings Panel to ensure continued compliance with bid price and stockholders' equity requirements for Capital Market listing.

Based in Berkeley, California, Profusa develops tissue-integrated sensors that detect and transmit medical-grade data. The company describes itself as being in the commercial stage and focuses on injectable biosensors and data platform technology for personal and medical applications.

The company stated the move was previously announced as part of its compliance plan with Nasdaq listing requirements. The information was disclosed in a press release issued by the company.